Teva to Distribute Medical Marijuana Inhaler Throughout Israel in 2017

Teva Pharmaceuticals and Syqe Medical say the device is the first in the medical cannabis sector that complies with pharmaceutical standards for inhalation.

Illustration: Marijuana plants at the Breath Of Life Pharma greenhouse in Israel.
Illustration: Marijuana plants at the Breath Of Life Pharma greenhouse in Israel. Jack Guez, AFP

An inhaler for administering medical cannabis for pain management is due to be distributed widely in Israel, including for home use, under an agreement signed Monday with Teva Pharmaceuticals. 

Syqe Medical, which produces the inhaler, and Teva said the inhaler is the first such device in the medical cannabis sector that complies with pharmaceutical standards for inhalation, which is the most efficient means for administering the substance. 

“Teva Israel is entering the field of medical cannabis out of a deep commitment to patients coping with pain, which is one of the company’s core therapeutic areas,” said its CEO, Avinoam Sapir, according to The Times of Israel.

The pocket-sized Syqe inhaler provides precise 100-microgram doses that allows patients to control delivery, overcoming the problem of standard dosages, one of the major barriers to adoption of medical cannabis by doctors. 

Tel Aviv-based Syqe has been using a similar device in Haifa’s Rambam Hospital for the last year, which has demonstrated that its dosing precision is superior to other modes of THC administration. 

Teva will be the exclusive marketer and distributor in Israel of the inhaler after it is cleared for home use by the Health Ministry in early 2017.

JTA contributed to this report.